If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Cetuximab is supplied as a sterile, preservative-free injectable liquid at concentrations of
2 mg/mL as a 100 mg/50 mL, single-use vial (NDC 66733-948-23) or
200 mg/100 mL, single-use vial (NDC 66733-958-23) (Erbitux Package Insert, 2016).
Do not freeze. Increased particulate formation may occur at temperatures at or below 32°F (0°C).
Store cetuximab vials under refrigeration at 36°F to 46°F (2°C to 8°C).
Preparations of cetuximab in infusion containers are chemically and physically stable at for up to
12 hours at 36°F to 46°F (2°C to 8°C)
8 hours at controlled room temperature 68°F to 77°F (20°C to 25°C) (Erbitux Package Insert, 2016).
Discard any unused portion of the vial (Erbitux Package Insert, 2016).
Enclosed Prescribing Information
Erbitux [package insert]. Indianapolis, IN: Eli Lilly and Company; 2016.
Date of Last Review: January 02, 2018